en

Immunoassay

REF **CMB0801 / CMB0802 / CMB0803 / CMB0804 / CMB0805**

50 tests*1 / 100 tests*1 / 100 tests*2 / 100 tests*5 / 50 tests*2

CA19-9 CLIA Microparticles

This assay is based on a chemiluminescent microparticle immunoassay (CLIA Microparticles) for the quantitative determination of CA19-9 (cancer antigen 19-9) in human serum.

Key to Graphical Symbols Used

LOT	batch code		use by
	manufacturer	Σ	contains sufficient for <n> tests
IVD	*in vitro* diagnostic medical device		temperature limitation
REF	catalogue number		consult instructions for use
EC REP	authorized representative in the European Community		

EC REP

OBELIS S.A.
Bd. Général Wahis, 53
1030 Brussels
Belgium

AUTOBIO DIAGNOSTICS CO., LTD.
No.87 Jingbei Yi Road
National Eco & Tech Development Area
Zhengzhou
China
450016

CE IVD

For any technical assistance please contact us in English at:
Email: customerservice@autobio.com.cn
Contact your local dealers for all product-related questions in your local language

Introduction

The CA19-9 is a carbohydrate antigen predominantly associated with gastrointestinal malignancies; pancreatic, colorectal, gastric and hepatic carcinomas.[1-3] The main application of CA19-9 is in the management of diagnosed pancreatic and colorectal cancers.[4-6] Immunochemically, CA19-9 antigen is the sialylated form of the blood group antigen Lewis.[7] Clinical studies indicate that CA19-9 assay levels have been found elevated in the serum with carcinomas of the exocrine pancreas, the colon and rectum, the stomach and lung cancer.[8,9] It has been shown that a persistent elevation in CA19-9 assay value following treatment may be indicative of occult metastatic and/or residual disease. A persistently rising CA19-9 assay value may be associated with progressive malignant disease and poor therapeutic response. A declining CA19-9 assay value may be indicative of a favorable prognosis and a good response to treatment.[10,11] Increased serum CA19-9 assay values have also been observed in patients with nonmalignant conditions such as hepatitis, cirrhosis, pancreatitis, and other gastrointestinal disease.[12] The CA19-9 concentration should always be interpreted taking into consideration other clinical data and should not be used as a cancer screening test.

Measurement Principle

This assay is based upon the two-step sandwich method. In the first step, the sample and CA19-9 antibody coated microparticles are combined. During the incubation, CA19-9 antigen present in the sample binds to the antibody coated the microparticles. After the washing, in the second step, Enzyme Conjugate is added to the reaction mixture. During the incubation, a complex is generated among the microparticles, the CA19-9 antigen within the sample and enzyme-linked antibodies by immunological reactions. Chemiluminescent Substrate is added and the complex catalyzes substrate, resulting in a chemiluminescent reaction. The resulting chemiluminescent reaction is measured as RLUs. The RLU is proportional to the amount of CA19-9 in the samples.

Materials provided

1. Calibrators

6 vials each containing 1.0 mL of calibrator A through F. The matrix is PBS (phosphate buffered saline) buffer containing bovine serum. Contains a selection of preservatives.
Calibrators provided ready to use.

2. Reagent pack

Reagent pack provided ready to use.

Σ	50*1	100*1	100*2	100*5	50*2
Microparticles Solution	1.2mL*1	2.3mL*1	2.3mL*2	2.3mL*5	1.2mL*2
Enzyme Conjugate	5.5mL*1	11.0mL*1	11.0mL*2	11.0mL*5	5.5mL*2
Sample Diluent	3.0mL*1	5.5mL*1	5.5mL*2	5.5mL*5	3.0mL*2

- Microparticles Solution

CA19-9 antibody coated microparticles in PBS buffer containing BSA. Contains a selection of preservatives.

- Enzyme Conjugate

Horseradish-peroxidase labeled mouse monoclonal anti-CA19-9 in Tris buffer containing BSA (bovine serum albumin). Contains a selection of preservatives.

- Sample Diluent

PBS containing bovine serum. Contains a selection of preservatives.

Assay Analyzers on which the kit can be used

- AutoLumo A2000 Plus
- AutoLumo A2000 Plus B
- AutoLumo A1000

The chemiluminescent microparticle immunoassay (CLIA Microparticles) is intended for use on Assay Analyzer which is AutoLumo A2000 Plus, AutoLumo A2000 Plus B or AutoLumo A1000.

Materials Required but not Provided

1. Assay Analyzer
2. Reaction vessel(s) for sample and reagent reaction
3. Sample cup(s) or tube(s) for sample containing
4. Diluent Universal
5. Chemiluminescent Substrate
6. System Wash for washing the pipetting needles
7. Wash Buffer used in the washing procedure
8. Distilled water or deionized water

Metrological Traceability of Calibrators

The measurand or analyte in the CA19-9 calibrators is traceable to the manufacturer's working calibrators. Traceability process is based on EN ISO 17511. The assigned values were established using representative samples from this lot of calibrator and are specific to the assay methodologies of the reagents. Values assigned by other methodologies may be different. Such differences, if present, may be caused by inter-method bias.

Warnings and Precautions

1. For professional use only.
2. Follow the instruction for use carefully. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this instruction for use.
3. Refer to the material safety data sheet and product labeling for any chemical hazards that may be present in this assay.
4. Handle the potentially contaminated materials and wastes safely according to local requirement.
5. This assay contains materials of animal origin. Bovine components originate from countries where BSE has not been reported.
6. Do not smoke, drink, eat or use cosmetics in the working area.
7. Wear protective clothing and disposable gloves when dealing with samples and reagents. Wash hands after operations.
8. Conduct the assay away from bad ambient conditions. e. g. ambient air containing high concentration corrosive gas such as sodium hypochlorite acid, alkaline, acetaldehyde and so on, or containing dust.
9. Do not use reagents beyond the labeled expiry date.
10. Do not mix or use components from kits with different batch codes.
11. When storing the calibrators, be certain the vials are securely sealed.
12. Ensure the microparticles are resuspended before loading it on the analyzer.
13. Avoid foam formation in all reagents and sample types (samples, calibrators and controls).
14. Do not substitute any reagent in this kit from other manufacturers or other lots.
15. When any damage to the protective packaging or any change of analytical performance is observed, do not use the kit.

Storage

1. Store the kit at 2-8 ℃. Do not freeze. Avoid strong light. When stored as directed, all reagents are stable until the expiration date.

2. Refrigerate the reagent pack at 2-10 ℃ for a minimum of 2 hours prior to use.
3. Store the unsealed reagents pack upright on the analyzer or 2-10℃ for a maximum of 28 days. After 28 days, the reagent pack must be discarded. Once they are removed from the analyzer, store them at 2-10℃ in an upright position.
4. Seal and return the remaining calibrators at 2-8 ℃ immediately after the experiment, under which conditions the stability will be retained for 1 month, for longer use, store opened calibrators in aliquots and freeze at -20 ℃, under which conditions the stability will be retained for 2 months. Avoid multiple freeze-thaw cycles, do not freeze-thaw more than 3 cycles.

Sample

1. Collect serum samples in accordance with correct medical practices.
2. Do not use heat-inactivated samples. Do not use sodium azide preservative in samples.
3. Do not use samples with obvious microbial contamination.
4. Sediments and suspended solids in samples may interfere with the test result which should be removed by centrifugation. Ensure that complete clot formation in serum samples has taken place prior to centrifugation. Some samples, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the sample is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results. Be sure that the samples are not decayed prior to use.
5. Prior to shipment, it is recommended that samples be removed from the clot, serum separator or red blood cells.
6. Use caution when handling patient samples to prevent cross contamination. Use of disposable pipettes or pipette tips is recommended.
7. Insufficient processing of sample, or disruption of the sample during transportation may cause depressed results.
8. Avoid grossly hemolytic, lipemic or turbid samples.
9. Cap and store the samples at 18-25 ℃ for no more than 8 hours, for longer use samples should be capped and stored at 2-8 ℃ up to 48 hours. Or freeze the samples that need to be stored or transported for more than 48 hours at -20 ℃. Avoid multiple freeze-thaw cycles. Mix thawed samples thoroughly by low speed vortex or by inverting 10 times. Visually inspect the samples, if layering or stratification is observed, continue mixing until samples are visibly homogeneous. After thawing, bring to room temperature and mix well by gently shaking.
10. Centrifuge the thawed samples containing red blood cells or particulate matter, or which are hazy or cloudy in appearance prior to use to ensure consistency in the results.
11. Note that interfering levels of fibrin may be present in samples that do not have obvious or visible particulate matter.
12. If proper sample collection and preparation cannot be verified, or if samples have been disrupted due to transportation or sample handling, an additional centrifugation step is recommended. Centrifugation conditions should be sufficient to remove particulate matter.
13. For optimal results, inspect all samples for bubbles. Remove bubbles with a tip prior to analysis. Use a new tip for each sample to prevent cross contamination.

Measurement Procedure

1. Check the consumable materials

- Verify adequate volume of consumable materials is present prior to running the test.
- Refer to the Assay Analyzer's operation manual.

2. Load the kit

- Mix contents of new (unpunctured) reagent packs by gently inverting pack several times before loading on the analyzer. Avoid foam formation in all reagents. Don't invert the open (punctured) packs. If necessary, shake gently to mix horizontally after the first loading.
- Read the bar code on the reagent pack automatically to obtain the required parameters for the test.
- If the bar code cannot be read in exceptional cases, they can be recognized manually.
- Refer to the Assay Analyzer's operation manual.

3. Order tests

- Place the sample cups or tubes on the sample rack, 25 μL of samples for each test. But considering the sample container and 150 μL of system dead volumes, which can be refer to the appropriate Assay Analyzer manuals for the minimum sample volume required.
- Load the sample rack and input the sample information on the system software interface.
- Select "run" to start the test, the analyzer automatically operates tests. It performs the following functions:
  - Moves the sample to the set point
  - Loads a reaction vessel into the process path
  - Aspirates and transfers sample into the reaction vessel
  - Adds Microparticle Solution and Sample Diluents to the reaction vessel
  - Mixes, incubates and washes the reaction mixture
  - Adds Enzyme Conjugate to the reaction vessel
  - Mixes, incubates and washes the reaction mixture
  - Add Chemiluminescent Substrate
  - Measures chemiluminescent emission to determine the quantity of CA19-9 in the sample
  - Discards the used reaction vessel
  - Calculates the result
- Refer to the Assay Analyzer's operation manual.

4. Calibrate the curve

- Analyzer can read the bar code on the reagent pack automatically to obtain the required parameters for the test.
- If the bar code cannot be read in exceptional cases, they can be recognized manually.
- Transfer the calibrators into the sample cups or tubes and place them on the sample rack. Conduct duplicate detection on the system.
- Load the sample rack and input calibrators' information on the system software interface.
- Select "run" to start the test and generate the calibration curve, calibration is required every 28 days.
- Once a calibration curve is accepted and stored, all subsequent samples may be tested without further calibration unless:
  - Controls are out of range after repeated measurements
  - A reagent kit and Chemiluminescent Substrate with new batch code is used
  - Beyond the expiration date of a calibration curve
  - Important parts of the analyzer are replaced or repaired.
- Refer to the Assay Analyzer's operation manual.

5. Dilute the sample

Samples with a CA19-9 value exceeding 1000 U/mL may be diluted via the program of the analyzer. Diluent Universal is used to dilute the samples. The software takes the dilution into account when reporting the result.

- The concentration of the sample after dilution should not be less than 200 U/mL.

Measurement Results

The sample test results are determined automatically by the system software. The amount of CA19-9 in the samples is determined from the measured light production by means of the stored calibration data. Refer to the Assay Analyzer's operation manual on reviewing sample results.

Control Procedure

The recommended control requirement for this assay is to purchase control materials separately and test them together with the samples within the same run. The result is valid if the control values fall within the acceptable ranges. When a control value is out of the specified range, it may indicate deterioration of the reagents or errors in technique. Associated test results may be invalid and may require retesting. Assay recalibration may be necessary. It is recommended that each laboratory establish its accepted range to ensure proper test performance.

Limitations of the Procedure

1. This assay is intended as an aid for the clinical diagnosis. Conduct this assay in conjunction with clinical examination, patient's medical history and other test results.
2. If the results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.
3. Heterophilic antibodies and rheumatoid factors in samples may interfere with test results. Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with *in vitro* immunoassays. Patients routinely exposed to animals or animal serum products can be prone to this interference and anomalous values may be observed. Additional information may be required for diagnosis. This kind of samples is not suitable to be tested by this assay.
4. Performance of this test has not been established with neonatal samples.
5. CA19-9 has a low clinical sensitivity and specificity as a tumor marker. Clinically an elevated CA19-9 value alone is not of diagnostic value as a test for cancer and should not be used in conjunction with other clinical manifestations (observations) and diagnostic parameters.
6. Patients who have received mouse monoclonal antibodies for either diagnosis or therapy can develop HAMA (human Anti-mouse antibodies). HAMA can produce either falsely high or falsely low values in immunoassays which use mouse monoclonal antibodies. Additional information may be required for diagnosis.
7. This test measures concentrations within the range of 2- 1000 U/mL. If CA19-9 concentrations above the measuring range to be expected, it is recommended to dilute samples with Diluent Universal, the recommended dilution is 1:4 of this test, under this condition, allowing samples to be up to approximately 5000 U/mL.

Biological Reference Interval

A normal value of <35 U/mL (95^{th} percentile) was obtained by testing serum samples from 524 individuals defined as normal by clinician. It is recommended that each laboratory establish its own normal range which may be unique to the population it serves depending upon geographical, patient, dietary, or environmental factors.

Performance Characteristics

1. Measurement Precision

3 samples were assayed in duplicate, twice per day across 20 testing days. Data from this study are summarized in the following table.

Sample	n	Mean (U/mL)	Within-run	Total
			%CV	%CV
1	80	28.69	2.25	5.37
2	80	65.32	3.54	4.71
3	80	142.84	2.14	4.30

*Representative data; results in individual laboratories may vary from these data.

2. Analytical Sensitivity

Limit of Blank: 1.0 U/mL
Limit of Detection: 2.0 U/mL
Limit of Quantitation: 5.0 U/mL with a coefficient of variation of $\leq$ 20 %.

3. Analytical Specificity

Cross reaction: the following substances and concentrations were tested and found no cross reaction with the test;

Substances	Concentration
CEA	500 ng/mL
CA125	400 U/mL
CA15-3	500 U/mL

Interference: No interference with 66 mg/dL of bilirubin, 500 mg/dL of hemoglobin, 1500 mg/dL of triglycerides.

4. Measurement Accuracy by Correlation

A comparison study was performed where samples were tested using this assay and a CA19-9 test which was already sale in the market. Data were analyzed and are summarized in the following table.

Correlation Method	Number of Samples	Intercept	Slope	Correlation Coefficient
Linear Regression	402	7.3634	0.9028	0.9287

5. High Dose Hook Effect

A sample spiked with CA19-9 up to 35,000 U/mL was determined, the concentration result obtained was $\geq$1000 U/mL.

Literature References

1. Koprowski H, Herlyn M, Steplewski Z, Sears H. Specific antigen in serum of patients with colon carcinoma. *Science*. 1981;212(4490):53-55.

2. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA19-9 serum course in pancreatic cancer. *Hepatogastroenterology*. 1998;45(19):253-259.

3. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas. *J. Clin. Oncol*. 1988;6(3):462-468.

4. Malesci A, Tommasini MA, Bonato C, et al. Determination of CA19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. *Gastroenterology*. 1987;92(1):60-67.

5. Farini R, Fabris C, Bonvicini P, et al. CA19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis☆. *European Journal of Cancer and Clinical Oncology*. 1985;21(4):429-432.

6. Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? *Br. J. Cancer*. 1998;77(2):325-328.

7. Koprowski H, Brockhaus M, Blaszczyk M, et al. Lewis blood-type may affect the incidence of gastrointestinal cancer. *Lancet*. 1982;1(8285):1332-1333.

8. Favero GD, Fabris C, Plebani M, et al. CA19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis. *Cancer*. 1986;57(8):1576-1579.

9. Kornek G, Depisch D, Temsch EM, Scheithauer W. Comparative analysis of cancer-associated antigen CA-195, CA19-9 and carcinoembryonic antigen in diagnosis, follow-up and monitoring of response to chemotherapy in patients with gastrointestinal cancer. *J. Cancer Res. Clin. Oncol*. 1991;117(5):493-496.

10. Willett CG, Daly WJ, Warshaw AL. CA19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. *Am. J. Surg*. 1996;172(4):350-352.

11. Kouri M, Pyrhönen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. *J Surg Oncol*. 1992;49(2):78-85.

12. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA19-9. *Clin. Chem*. 1983;29(3):549-552.